Clinical Trial Detail

NCT ID NCT01244750
Title Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

chronic myeloid leukemia

Therapies

Imatinib

Dasatinib

Nilotinib

Age Groups: adult

No variant requirements are available.